Efficacy and safety of fingolimod in stroke: A systemic review and meta-analysis

Table 6 Overall standard mean difference or pooled risk ratio via random-effects model and pooled risk ratio of remaining studies after the study with the highest quality is omitted

Method	Overall SMD or RR (95%CI)	Test of heterogeneity
		I2 (%)	P
Random-effects model
CD8+ T cells	-3.59 (-4.37, -2.80)	0.0	0.737
Lesion volume	-0.17 (-0.75, 0.42)	0.0	0.917
mBI score	2.43 (1.59, 3.26)	10.6	0.290
RR of fever	0.93 (0.37, 2.32)	0.0	0.864
RR of suspected lung infection	0.90 (0.33, 2.43)	0.0	0.876
RR of adverse events occurring at least once	0.82 (0.36, 1.87)	0.0	0.995
Article deleted
Zhu et al[17] (RR of fever)	0.78 (0.23, 2.68)	0.0	0.723
Zhu et al[17] (RR of suspected lung infection)	0.78 (0.23, 2.68)	0.0	0.723
Tian et al[18] (RR of adverse events occurring at least once)	0.84 (0.33, 2.18)	0.0	0.969

SMD: Standard mean difference; RR: Risk ratio; CD8⁺ T cell: T-lymphocytes with cluster of differentiation 8 expression; Lesion volume: Infarction or hematoma volume; mBI score: Modified Barthel index score.